Deerfield puts up $635M to create New York City biotech campus 

345 Park Avenue South, the building being renovated by Deerfield (RFR)

Deerfield Management is placing a big bet on the New York City biotech scene. The investment group is set to spend $635 million to set up a life science campus in midtown Manhattan, adding capacity in a city that has struggled to establish itself as a biotech hot spot. 

At the 12-story building, Deerfield plans to create 300,000 square feet of life sciences space, more than two-thirds of which will be suitable for wet lab use. Deerfield is now renovating the building, which was previously occupied by the advertising agency Digitas, with a view to bringing the capacity online in 2021.

The project is the latest sign that New York City can address the capacity constraints that have limited its presence in the biotech industry. Backed by an administration keen to turn the city into a biotech hot spot, developers are following the lead of the Alexandria Center for Life Science and adding new capacity.

Survey

Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

Deerfield is working with the New York City Economic Development Corporation (NYCEDC) on the project, including through a $30 million investment in a workforce development program. NYCEDC expects the program to support almost 5,000 New Yorkers involved in the city’s life sciences sector. The campus itself is expected to create 1,400 life science jobs. 

“The 1,400 jobs coming to the Life Sciences Campus is just another signal, on top of our numerous hospitals and health care facilities, that the East Side of Manhattan is quickly becoming a top destination nationwide for healthcare and life science jobs,” Carlina Rivera, a New York City councilwoman, said in a statement.

Deerfield shared details of the New York City campus alongside news that it plans to invest more than $2 billion in research and seed funding by 2030. The investor currently manages around $10 billion.

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

J&J and Ethicon reached a deal with the attorneys general of 41 states and DC, agreeing to pay nearly $117 million.